title: Time and out-of-pocket costs associated with respiratory syncytial virus hospitalization of infants.
abstract: OBJECTIVE
  The objective of this study was to quantify time spent plus out-of-pocket costs associated with confirmed respiratory syncytial virus (RSV) hospitalization of infants not prophylaxed against RSV.
  
  
  METHODS
  A prospective survey was carried out at multiple tertiary care hospitals in the United States.
  
  
  METHODS
  The patients consisted of a consecutive sample of infants <12 months, born between 33 and 35 weeks of gestation. One site also enrolled full-term infants hospitalized with confirmed RSV. Daily patient census identified eligible patients. Consenting caregivers of eligible subjects (n=84, 1 refusal) were interviewed on discharge day and by telephone approximately 30 days following discharge regarding time and out-of-pocket costs due to RSV.
  
  
  RESULTS
  Total average out of pocket expenses were 643.69 US dollars (range 21-16,867 US dollars; SD 2,403 US dollars) for premature and 214.42 US dollars (range 6-827 US dollars; SD 218 US dollars) (P=.0158) for full-term subjects. Total average economic burden per admission was 4517.07 US dollars for premature and 2135.30 US dollars for full-term infants, including the value of lost productivity but excluding inpatient hospital and physician bills and lost income. Premature infants (n=48) had longer hospital stays (mean 6.9 days; SD 7.5 vs. 3.4 days; SD 2.6 days) (P=.001) with an associated mean total time spent by up to 5 adults of 281.7 hours (range 25-2819.7 hours; SD 465.8 hours) versus a mean of 139.7 hours (range 31.8-561.3 hours; SD 118.1 hours) for term infants (P=.109). Time and out-of-pocket costs continued after discharge.
  
  
  CONCLUSIONS
  RSV hospitalization of infants is associated with substantial, previously unmeasured time and monetary losses. These losses continued following discharge. The economic burden on families and society appears heavier for infants born at 33 to 35 weeks of gestation than for full-term infants.
authors.affiliation: MedImmune, Inc., Gaithersburg, MD 20878, USA. Leaders@MedImmune.com
authors.forename: Shelah
authors.initials: S
authors.lastname: Leader
authors.forename: Harry
authors.initials: H
authors.lastname: Yang
authors.forename: John
authors.initials: J
authors.lastname: DeVincenzo
authors.forename: Phillip
authors.initials: P
authors.lastname: Jacobson
authors.forename: James P
authors.initials: JP
authors.lastname: Marcin
authors.forename: Dennis L
authors.initials: DL
authors.lastname: Murray
mesh_terms: D017281:Cost of Illness; D003365:Costs and Cost Analysis; D005260:Female; D005382:Financing, Personal; D005865:Gestational Age; D017721:Hospital Costs; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D015278:Intensive Care Units, Pediatric; D007902:Length of Stay / Q000191:economics; D008297:Male; D011446:Prospective Studies; D018357:Respiratory Syncytial Virus Infections / Q000191:economics*